<DOC>
	<DOCNO>NCT00004801</DOCNO>
	<brief_summary>OBJECTIVES : Assess safety long-term efficacy monoclonal factor IX concentrate patient factor IX deficiency .</brief_summary>
	<brief_title>Phase I/II Study Monoclonal Factor IX Concentrate Factor IX Deficiency</brief_title>
	<detailed_description>PROTOCOL OUTLINE : Patients receive monoclonal factor IX replacement therapy inpatient . Patients satisfactory response receive therapy need bleed 36 month home .</detailed_description>
	<mesh_term>Hemophilia B</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Patients factor IX deficiency .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 1998</verification_date>
	<keyword>hematologic disorder</keyword>
	<keyword>rare disease</keyword>
</DOC>